99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization

Journal of Nuclear Medicine Technology

Pradeep Bhambhvani¹  Devaki Shilpa Surasi¹  Janis O’Malley¹ 

[1] Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, AlabamaDivision of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama Division of Molecular Imaging and Therapeutics, Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama

关键词: ^99mTc-tilmanocept;    Lymphoseek;    sentinel lymph node mapping;    molecular imaging;   

DOI  :  10.2967/jnmt.115.155960

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Preoperative lymphatic mapping in conjunction with intraoperative γ-probe detection is widely used for sentinel node localization in melanoma, breast cancer, and other malignancies. 99mTc-radiocolloids have been the standard radiotracers used for sentinel node mapping. 99mTc-tilmanocept is a receptor-binding molecular imaging agent approved by the U.S. Food and Drug Administration for lymphatic mapping and lymph node localization in breast cancer, melanoma, clinically node-negative squamous cell carcinoma of the oral cavity, and other solid tumors. It has several advantages over conventional radiocolloids, including rapid injection site clearance, high sentinel node extraction, and low distal node accumulation, which can lead to efficient resource use.

【 授权许可】

Unknown